Daniel J. Kruger, PhD

Cannabis has been used medically for thousands of years. Following the State-level establishment of medical Cannabis programs, we began a research program on the medicinal use of Cannabis and its relationship with mainstream health care systems. After the 2018 Farm Bill, a wide variety of cannabinoids became available on commercial markets. As Cannabis legalization continues to expand, it is crucial for harm reduction efforts to recognize that cannabis differs significantly from other substances like tobacco and alcohol. We conducted the first large surveys of individuals using products such as delta-8-THC and THC-O-acetate. Legal, scientific, and social landscapes for psychedelics are changing rapidly and personal use of psychedelics is increasing. It is critical to conduct research informing psychedelic policies and practices to maximize benefits and minimize costs, risks, and harms to individuals and society.